Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost

Robert D Fechtner, Paul Harasymowycz, Donald R Nixon, Steven D Vold, Fiaz Zaman, Julia M Williams, David A Hollander, Robert D Fechtner, Paul Harasymowycz, Donald R Nixon, Steven D Vold, Fiaz Zaman, Julia M Williams, David A Hollander

Abstract

Objective: To evaluate the additive intraocular pressure (IOP)-lowering efficacy and safety of fixed-combination brimonidine 0.2%/timolol 0.5% compared with timolol 0.5% at peak and trough effect when used as therapy adjunctive to latanoprost 0.005% in patients with glaucoma or ocular hypertension who require additional IOP lowering.

Methods: In this prospective, randomized, multicenter, investigator-masked, parallel-group study, patients were treated with latanoprost monotherapy for at least four weeks prior to baseline. At baseline on latanoprost, patients with IOP ≥21 mmHg in at least one eye were randomized to twice-daily fixed brimonidine-timolol (n = 102) or timolol (n = 102), each adjunctive to latanoprost for 12 weeks. IOP was measured at 8 am and 10 am at baseline, week 6, and week 12 and evaluated in the per protocol population. The primary efficacy endpoint was peak IOP lowering at 10 am, week 12. Safety measures included adverse events.

Results: Baseline mean IOP was similar at 10 am in the treatment groups (brimonidine-timolol 23.4 mmHg; timolol 23.0 mmHg). The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001). Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a ≥20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12. Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients. Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.

Conclusion: Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension. Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.

Keywords: brimonidine; drug combinations; glaucoma; intraocular pressure; ocular hypertension; timolol.

Figures

Figure 1
Figure 1
Study design and patient flow through the study. Abbreviation: IOP, intraocular pressure.
Figure 2
Figure 2
Mean change from latanoprost-treated baseline intraocular pressure at each time point after addition of fixed-combination brimonidine or timolol. Error bars, standard error of the mean. Abbreviation: IOP, intraocular pressure.
Figure 3
Figure 3
Percentage of patients achieving specified intraocular pressure levels at both the 8 am and 10 am measurements at week 12. Abbreviation: IOP, intraocular pressure.
Figure 4
Figure 4
Percentage of patients with at least a one grade increase from latanoprost-treated baseline in severity scores on biomicroscopy at week 12.

References

    1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713.
    1. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006;22(5):971–976.
    1. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine–0.5% timolol fixed-combination therapy vs mono-therapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: A 12-month randomized trial. Arch Ophthalmol. 2006;124(9):1230–1238.
    1. Goñi FJ; Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol. 2005;15(5):581–590.
    1. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15(2):132–135.
    1. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863–868.
    1. Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13(2):130–136.
    1. Crichton ACS. Timolol/brimonidine combination therapy in glaucoma management. Clin Surg J Ophthalmol. 2005;23:356–359.
    1. Ahmed I. CEED II: An in-depth look at the latest findings. Clin Surg J Ophthalmol. 2007;25:1–5.
    1. Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidine- timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009;25(7):1645–1653.
    1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440.
    1. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121(1):48–56.
    1. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol. 1999;128(6):692–696.
    1. Higginbotham EJ, Feldman R, Stiles M, Dubiner H Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: One-year randomized trial. Arch Ophthalmol. 2002;120(7):915–922.
    1. Pfeiffer N European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240(11):893–899.
    1. Olander K, Zimmerman TJ, Downes N, Schoenfelder J Xalacom/Latanoprost Study Group. Switching from latanoprost to fixed- combination latanoprost-timolol: A 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther. 2004;26(10):1619–1629.
    1. Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2008;24(5):1435–1442.
    1. Feldman RM, Tanna AP, Gross RL, et al. Additivity Study Group. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004% Ophthalmology. 2007;114(7):1248–1254.
    1. Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma. 2000;9(3):235–238.
    1. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: A 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005;21(4):337–348.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅